Lifescan and ResMed team up

Johnson & Johnson blood glucose meter maker Lifescan and sleep apnea treatment device manufacturer ResMed will co-market their devices under an exclusive agreement announced June 10. The firms will focus on educational and cross-promotional efforts based on research about the overlap of type 2 diabetes and sleep-disordered breathing. According to a June 7 consensus statement from the International Diabetes Foundation, recent studies suggest that up to 40% of people with obstructive sleep apnea have diabetes, and conversely, more than 50% of people with type 2 diabetes suffer from some form of sleep disorder. ResMed is currently sponsoring the 230-patient, randomized GLYCOSA study to assess the effectiveness of continuous positive airway pressure therapy in improving glycemic control in type 2 diabetes patients with newly diagnosed obstructive sleep apnea